If you are looking for another interesting company to diligence, check out COGT. They are trying to develop a therapeutic that would compete with BPMC's lead drug AYVAKIT® (avapritinib) to treat Systemic Mastocytosis (SM). BPMC announced yesterday that it agreed to be acquired by SNY for ~$9B, whereas COGT has a current market cap around $650M and EV ~$500M. Thus, if COGT were successful to develop a therapeutic to displace AYVAKIT, investors would be handsomely rewarded. COG

Summary:

Summary

Summary

First posted 1/19/2023; last updated 3/1/23

Last updated 3/1/23

SUMMARY Biotech stocks were up ~14% last week The huge biotech stock week was driven mainly by biotech M&A activity It's unlikely that...

(Originally posted 7/25/2022, updated 7/27/22) Summary BPIQ monitors mergers and acquisitions (M&A's) of smid-cap biopharmas Acquisition...